AUTHORS
Mark David Orland, MD, PhD, Aashray Mandala, BS2, Nandini Rajaram Siva, MD3, Serhan Unlu, MD4, Zachary Brady, BS5, Atsushi Marumo, MD6, Kartik Lakhotiya, MS7, Carmelo Gurnari, MD,PhD8, Valeria Visconte, PhD9, Jaroslaw P. Maciejewski, MD, PhD, FACP10
AFFILIATIONS
1 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Background: Thrombosis is the leading cause of morbidity and mortality in paroxysmal nocturnal hemoglobinuria (PNH), yet clinical recognition has historically centered on unusual-site venous thrombosis, particularly Budd-Chiari syndrome. Although complement inhibition substantially reduces thrombotic risk (21 vs 40 events per 1,000 patient-years; 2-year cumulative incidence 3.9% vs 18.3%), cerebrovascular manifestations remain poorly recognized, with prior reports focused predominantly on cerebral venous sinus thrombosis (CVST) and limited to case reports or small series. We hypothesized that arterial ischemic stroke is an underrecognized initial presentation of PNH, particularly among patients with small clones, contributing to delayed diagnosis and preventable recurrent thrombosis.
Methods and Results: To estimate the frequency of arterial cerebrovascular presentations at the population level, we analyzed a federated multi-institutional electronic health record dataset (COSMOS) comprising 489 patients with PNH, restricting analysis to arterial ischemic stroke and excluding CVST. Ninety-one patients (18.6%) experienced an arterial ischemic stroke before PNH diagnosis, including 75 in whom stroke was the initial thrombotic event and 16 with recurrent cerebrovascular events. Overall, 313 patients (64%) experienced any thrombotic event before recognition of PNH, indicating that delayed diagnosis remains common across health systems.
We next evaluated 422 consecutive patients presenting with arterial ischemic stroke at our institution. Conventional stroke mechanisms, including atrial fibrillation, patent foramen ovale, infective endocarditis, and carotid stenosis, were evaluated and excluded in patients ultimately diagnosed with PNH, raising suspicion for an underlying PNH-associated thrombotic mechanism. Despite readily available flow cytometry, only 33 patients (7.8%; mean age 47 ± 12 years) underwent PNH clone analysis. Among patients selected for PNH testing, 16 (48%; 43 ± 7 years) harbored a GPI-deficient clone, and 5 (40 ± 8 years) received a new diagnosis of PNH in which arterial ischemic stroke represented the presenting or antecedent manifestation, corresponding to 3.8% and 1.2% of the full stroke cohort.
Arterial stroke preceded PNH diagnosis by one month to five years. Four patients had unexplained cytopenias accompanied by a characteristic hemolytic-thrombotic laboratory signature, including anemia (hemoglobin 7-10 g/dL), thrombocytopenia (often <100 ×10?/L), elevated LDH (up to 897 U/L), low haptoglobin (as low as 13 mg/dL), and markedly elevated D-dimer (up to 2,860 ng/mL), yet neither PNH clone testing nor comprehensive hemolysis evaluation was pursued, indicating that diagnostic clues were present but unrecognized.
Notably, all arterial ischemic strokes occurred before recognition of PNH and therefore before initiation of complement inhibition. Two patients experienced recurrent cerebrovascular events before diagnosis, including one who developed a third ischemic stroke after discontinuing eculizumab, illustrating recurrent arterial thrombosis in the absence of complement inhibition. Arterial ischemic stroke occurred across a broad spectrum of granulocyte clone sizes (1.8%-52%), suggesting that arterial ischemic stroke may occur across a broader spectrum of clone sizes than traditionally appreciated. Patients with PNH-associated stroke were younger than the typical ischemic stroke population, with mean age decreasing across screened, clone-positive, and newly diagnosed patients (47, 43, and 40 years, respectively) compared with approximately 72 years.
Conclusions: Arterial ischemic stroke is an underrecognized initial presentation of PNH that frequently precedes diagnosis by months to years and is identified in patients younger than the typical stroke population. Unlike prior studies focused primarily on CVST, this study characterizes arterial cerebrovascular disease across population-scale and institutional cohorts. Notably, fewer than 8% of consecutive arterial stroke patients underwent clone testing, indicating that current practice is unlikely to identify PNH-associated stroke. These findings support PNH clone testing in younger patients with unexplained arterial ischemic stroke accompanied by cytopenias, laboratory evidence of hemolysis, or thrombotic features disproportionate to conventional vascular risk factors.
DISCLOSURES
Mark David Orland, MD, PhD: No relevant conflicts of interest to declare.